Silva-Vidal KV, Méndez-Sánchez N

Idioma: Ingles.
Referencias bibliográficas: 7
Paginas: 574-575
Archivo PDF: 62.91 Kb.

FRAGMENTO

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Geneva: Hepatitis C fact sheet. In: World Health Organization, 2012.

2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013: 57: 1333-42. doi: 10.1002/hep.26141.

3. Poordad F, McCone J, Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011: 364: 1195-206. doi: 10.1056/NEJMoa1010494.

4. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011: 364: 2405-16. doi: 10.1056/NEJMoa1012912.

5. Hagan LM, Sulkowski MS, Schinazi RF. Cost analysis of sofosbuvir/ ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. Hepatology 2014: 60: 37-45. doi: 10.1002/ hep.27151.

6. Mendez-Sanchez N. The socioeconomic impact of hepatitis C infection and liver transplantation in Mexico. Ann Hepatol 2012: 11: 550-1.

7. Szabo SM, Bibby M, Yuan Y, Donato BM, Jimenez-Mendez R, Castaneda-Hernandez G, Rodriguez-Torres M, et al. The epidemiologic burden of hepatitis C virus infection in Latin America. Ann Hepatol 2012: 11: 623-35.